CHRNA7 and schizophrenia: Multiple clinical trials with α7 nAChR agonists failed to demonstrate efficacy in patients with cognitive deficits or schizophrenia, suggesting decreased expression of functional α7 nAChRs in these patients’ neuronal cells [32,33].